TDs call on pharma company to work with HSE to give access to life-changing drug Skyclarys
Fine Gael TDs met Biogen over Skyclarys for Friedreich’s Ataxia after Ireland’s HSE recommended against funding. Skyclarys was approved by the European Medicines Agency in Feb 2024 and costs about €288,000 per patient per year. Around 200 Irish patients lack access despite availability elsewhere. A letter from Fianna Fáil MPs urged Health Minister and HSE to reverse the decision.
How this was made
The 30-second read
Why it matters
The newest element is the direct meeting with Biogen and the request to consider a compassionate access program before an HSE senior management meeting on 25 August, increasing the chance of near-term reimbursement or access-related developments.
Market read
This is a payer-access and political pressure story tied to a specific drug and manufacturer, with a near-term procedural deadline (25 August) but no confirmed funding change.
What to watch
The article does not quantify likelihood of reversal, nor does it provide Biogen’s response or any concrete change in reimbursement policy.
Background
Skyclarys (for Friedreich’s Ataxia) was approved by the EMA in Feb 2024 and is available in other European countries, but Ireland’s HSE drug group recommended against funding, leaving about 200 patients without access.
Ticker impact
Fine Gael TDs met Biogen, maker of Skyclarys, to urge engagement with Ireland’s HSE after a recommendation against funding leaves ~200 patients uncovered.
Limited direct impact on Biogen’s consolidated financials is likely, but reimbursement headlines could drive short-term sentiment around rare-disease access and payer negotiations.
The article describes advocacy and a request for a compassionate access program, but provides no new financial terms, guidance, or confirmed funding reversal.
Market effects
Highlights payer access friction for rare-disease, high-cost therapies in Europe, which can affect sentiment around reimbursement risk for biotech.
Ireland-specific access delay for Skyclarys may increase political scrutiny of HSE drug funding decisions.
Could be read across to other EU markets’ reimbursement negotiations for similar high-cost rare-disease drugs.
Counterpoint
Even if political pressure grows, HSE funding decisions may remain unchanged, making the incremental trading signal small.
Key entities
- companyBiogen
Manufacturer of Skyclarys, asked to engage with HSE and consider a compassionate access program.
- government_health_agencyHSE
Ireland’s Health Service Executive, whose drug group recommendation against funding is driving the dispute.
- drugSkyclarys
Disease-modifying treatment for Friedreich’s Ataxia; not funded for ~200 patients in Ireland.
